Latham & Watkins Advises on Bambusa Therapeutics’ Upsized US$168.9 Million IPO

Bambusa Therapeutics, Inc. (Nasdaq: BBTX) (Bambusa), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, has announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of US$16 per share. The gross proceeds to Bambusa from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bambusa, are expected to be US$168.9 million. In addition, Bambusa has granted the underwriters a 30-day option to purchase up to an additional 1,583,333 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Bambusa.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Rachel Moore and Sam Berry.